Science and Research

For the future of science and research

We believe that our support for young medical and scientific talents is a critical investment in the future. For this reason, the DKMS Stiftung Leben Spenden awards the John Hansen Research Grant (formerly: Mechtild Harf Research Grant).

Last updated: 03/08/2020

Launched in 2015, the John Hansen Research Grant (known until 2019 as the Mechtild Harf Research Grants) is intended to provide financial support to as many as four talented young scientific researchers. The grants are worth €240,000 ($270,000) for each recipient, spread over a period of three years. Applicants must have completed their doctorate within the last twelve years. The research area of the project they submit should be in the field of stem cell therapy, and it must aim to effectively support and advance the fight against blood cancer long-term.

In 2019, the grants were renamed in honor of John A. Hansen, who dedicated his life’s work to the causes of graft-versus-host disease and the fight against it. Hansen was an outstanding oncologist, an excellent immunogeneticist at the renowned Fred Hutchinson Cancer Research Center in Seattle, and a compassionate and empathetic physician. His outstanding achievements in the field of hematopoietic stem cell transplantation were instrumental in making blood stem cell and bone marrow transplants more effective and safer – giving numerous patients a second chance at life.

As a long-standing member of the Board of the DKMS Stiftung Leben Spenden (Foundation for Giving Life) and the DKMS Medical Council, Hansen was an integral part of the DKMS family. That is why, after he passed away on July 31, 2019, at the age of 76, the Mechtild Harf Research Grants were renamed in his honor. For eligibility criteria and more information on the John Hansen Research Grant, visit www.dkms.org/john-hansen-grant or send an email to grant@dkms.org.

Help us to register even more lifesavers

We’d love it if you could help us to get more people on the registry and thus give new hope for life to many blood cancer patients.